Arrowhead outlines pivotal 2026 milestones with REDEMPLO launch, $1.33B capital boost, and robust cardiometabolic pipeline
Source: SeekingAlpha
2026-02-06 00:35:07 ET
More on Arrowhead Pharmaceuticals
- Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript
- Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches - Slideshow
- Arrowhead Pharmaceuticals Q1 2026 Earnings Preview
- Arrowhead Pharmaceuticals prices upsize convertible notes offering to $625M and stock offering at $64.50
Read the full article on Seeking Alpha
For further details see:
Arrowhead outlines pivotal 2026 milestones with REDEMPLO launch, $1.33B capital boost, and robust cardiometabolic pipeline
Arrowhead Pharmaceuticals Inc.
NASDAQ: ARWR
ARWR Trading
2.82% G/L:
$59.19 Last:
950,124 Volume:
$59.10 Open:
ARWR Latest News
February 24, 2026 07:30:00 am
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
February 17, 2026 09:05:00 am
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
ARWR Stock Data
$8,824,478,533
134,991,031
3.4%
157
N/A
Biotechnology & Life Sciences
Healthcare
US
Pasadena
